Skip to main content

Drug Interactions between fosphenytoin and idelalisib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

fosphenytoin idelalisib

Applies to: fosphenytoin and idelalisib

GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter. In healthy volunteers, administration of a single 150 mg dose of idelalisib with the potent CYP450 3A4 and P-gp inducer rifampin (600 mg daily for 8 days) decreased mean idelalisib peak plasma concentration (Cmax) by 58% and systemic exposure (AUC) by 75%.

MANAGEMENT: Concomitant use of idelalisib with potent CYP450 3A4 or P-gp inducers such as carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John's wort should generally be avoided due to the potential for reduced efficacy.

References (1)
  1. (2014) "Product Information. Zydelig (idelalisib)." Gilead Sciences

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer